Introduction
For biotechnology, pharmaceutical, agricultural biotechnology, and life sciences innovators, international patent protection frequently begins with a Patent Cooperation Treaty (PCT) application. However, obtaining enforceable patent rights in Europe requires a critical next step: entering the European regional phase before the European Patent Office (EPO).
One of the most important considerations during this transition involves nucleotide and amino acid sequence listings. Since the global implementation of WIPO Standard ST.26, applicants entering the European phase must carefully assess sequence listing requirements, applicable standards, compliance obligations, and filing deadlines. Failure to meet EPO sequence listing requirements can result in additional fees, procedural complications, or delays in examination.
This guide explains how sequence listings are handled when transitioning from a PCT application to a European patent application, the differences between ST.25 and ST.26 standards, and best practices for ensuring a smooth Euro-PCT entry.
Understanding Euro-PCT National Phase Entry
A PCT application does not itself result in a patent grant. Instead, it provides a unified international filing system that allows applicants to seek protection in multiple jurisdictions through a single application. To continue prosecution in Europe, applicants must enter the regional phase before the European Patent Office within the applicable deadline, generally 31 months from the earliest priority date.
Once the European phase is entered, the EPO examines the application under the provisions of the European Patent Convention (EPC), including rules governing biological sequence disclosures.
Why Sequence Listings Matter in Biotechnology Patents
Patent applications involving biological material frequently disclose:
- DNA sequences
- RNA sequences
- cDNA constructs
- Peptides
- Proteins
- Antibodies
- Modified nucleotide sequences
- Genetically engineered biological materials
To facilitate examination and database searching, patent offices require these sequences to be presented in a standardized format known as a sequence listing. Sequence listings enable patent examiners and researchers to identify, compare, and analyze disclosed biological sequences efficiently.
The Transition from ST.25 to ST.26
A major change in global patent practice occurred with the implementation of WIPO Standard ST.26.
Prior to July 1, 2022, sequence listings were filed under WIPO Standard ST.25. Beginning July 1, 2022, WIPO and participating patent offices worldwide adopted ST.26, which requires sequence listings to be submitted in XML format.
Key objectives of ST.26 include:
- Improved data quality
- Enhanced machine readability
- Better integration with biological databases
- Consistent international practices
- Automated validation capabilities
The transition applies internationally across PCT, national, and regional patent systems.
Which Standard Applies When Entering the European Phase?
One of the most common questions during Euro-PCT entry is whether an application must be converted to ST.26 when entering Europe.
The answer depends on the international filing date of the PCT application.
PCT Applications Filed Before July 1, 2022
If the international application was filed on or before June 30, 2022:
- WIPO Standard ST.25 remains applicable.
- The original ST.25 sequence listing generally remains valid.
- Conversion to ST.26 is not automatically required solely because the application enters the European phase after July 1, 2022.
PCT Applications Filed On or After July 1, 2022
If the international filing date is July 1, 2022, or later:
- WIPO Standard ST.26 applies.
- Sequence listings must comply with XML-based ST.26 requirements.
- The EPO expects the sequence listing to conform to the international filing standard.
Importantly, the determining factor is the filing date of the PCT application, not the priority date.
EPO Requirements During Regional Phase Entry
When a Euro-PCT application contains nucleotide or amino acid sequences, an electronic sequence listing complying with the applicable WIPO standard must be available to the EPO by the expiration of the 31-month period for European phase entry.
In many cases, no additional submission is necessary because the sequence listing was already:
- Included in the original PCT filing,
- Submitted during the international phase under PCT procedures, or
- Made available through WIPO’s systems and accessible to the EPO.
However, applicants should verify that the sequence listing is complete, accessible, and technically compliant before regional phase entry.
ST.26 XML Sequence Listings: What Makes Them Different?
Compared with ST.25, ST.26 introduces substantial structural changes.
Key characteristics include:
XML-Based Format
ST.26 requires sequence listings to be submitted as structured XML files rather than text-based sequence listings. This allows automated processing and validation.
Expanded Biological Data Categories
ST.26 accommodates modern biotechnology developments, including sequence types that were not adequately addressed under ST.25.
Standardized Qualifiers
Applicants must provide sequence-related information using predefined qualifiers and controlled vocabulary structures.
Automated Validation
Sequence listings can be electronically validated for compliance before filing, reducing formal defects and inconsistencies.
Using WIPO Sequence for Compliance
WIPO provides a dedicated software platform called WIPO Sequence that allows applicants to prepare compliant ST.26 sequence listings.
The software enables users to:
- Create XML sequence listings
- Validate compliance
- Manage biological sequence data
- Generate submission-ready files
For applicants filing new biotechnology applications under ST.26, use of WIPO Sequence has become an industry standard.
Common Challenges During Euro-PCT Transition
Missing Sequence Listings
One of the most common issues arises when the sequence listing submitted during the international phase is incomplete, unavailable, or technically defective.
Applicants should review the international file well before the 31-month deadline to identify any deficiencies.
ST.25 and ST.26 Confusion
Applicants sometimes assume that all Euro-PCT applications must be converted to ST.26.
In reality, the applicable standard depends on the PCT filing date. Misunderstanding this distinction can create unnecessary work and procedural complications.
Added-Matter Concerns
When converting sequence data between standards, applicants must ensure that no new technical information is introduced. Under European patent law, added subject matter can create serious validity and prosecution issues.
Patent practitioners therefore carefully review any converted sequence listing to confirm consistency with the original disclosure.
Best Practices for Applicants
To ensure a smooth transition from the PCT system to the European patent system, applicants should:
Review Sequence Listings Early
Verify that all biological sequences disclosed in the application are correctly represented.
Confirm Applicable Standards
Determine whether ST.25 or ST.26 governs the application based on the international filing date.
Validate XML Files
For ST.26 applications, perform validation checks before European phase entry.
Coordinate with European Counsel
European patent attorneys can review sequence listing compliance and identify potential procedural risks.
Monitor the 31-Month Deadline
Ensure that all requirements for regional phase entry, including sequence listing availability, are satisfied before expiration of the applicable time limit.
Strategic Importance for Biotechnology Patent Portfolios
Sequence listings are not merely administrative documents. They often define the scope and support of biotechnology inventions involving genes, proteins, antibodies, vaccines, diagnostic markers, and engineered biological systems.
Errors in sequence disclosures can affect:
- Patentability
- Sufficiency of disclosure
- Examination outcomes
- Enforcement strategies
- Portfolio value
- Licensing opportunities
Consequently, sequence listing compliance should be treated as an essential component of international patent strategy rather than a procedural formality.
Conclusion
The transition from a PCT application to a European patent application involves more than simply entering the regional phase. For biotechnology and life sciences inventions, sequence listing compliance plays a central role in ensuring successful prosecution before the EPO.
Applicants must determine whether ST.25 or ST.26 applies based on the international filing date, confirm that a compliant sequence listing is available to the EPO at regional phase entry, and carefully manage any sequence-related updates to avoid procedural or substantive issues. By understanding the EPO’s sequence listing requirements and planning ahead, applicants can streamline Euro-PCT entry and strengthen the protection of valuable biological innovations throughout Europe.